NGM Biopharmaceuticals: Funding, Investors & Team (Oct 2026)
NGM Biopharmaceuticals is a privately-owned company dedicated to finding groundbreaking medicines that significantly enhance human health. Using new clinical and genetic findings, the company has developed unique methods to uncover potential treatments for metabolic and heart conditions. Their primary focus is on the gastrointestinal endocrine system, aiming to discover new factors related to type 2 diabetes and its resolution in patients who have had gastric bypass surgery.
NGM Biopharmaceuticals has raised $122M across 1 funding round on record, the most recent a Series A of $122M announced in Jul 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NGM Biopharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jul 2024.
NGM Biopharmaceuticals Funding Rounds
NGM Biopharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
NGM Biopharmaceuticals Funding Compared to Other Biotechnology Startups
NGM Biopharmaceuticals' latest round of $122M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NGM Biopharmaceuticals in Biotechnology and South San Francisco
Companies Similar to NGM Biopharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
NGM Biopharmaceuticals Funding FAQs
What does NGM Biopharmaceuticals do?
NGM Biopharmaceuticals is a privately-owned company dedicated to finding groundbreaking medicines that significantly enhance human health. Using new clinical and genetic findings, the company has developed unique methods to uncover potential treatments for metabolic and heart conditions. Their primary focus is on the gastrointestinal endocrine system, aiming to discover new factors related to type 2 diabetes and its resolution in patients who have had gastric bypass surgery.
How much funding has NGM Biopharmaceuticals raised?
NGM Biopharmaceuticals has raised $122M across 1 round on record. The most recent is a Series A of $122M announced in Jul 2024.
When did NGM Biopharmaceuticals last raise funding?
NGM Biopharmaceuticals' most recent funding round on record is a Series A of $122M, announced in Jul 2024.
Who founded NGM Biopharmaceuticals?
FundedIQ lists Kamala Chaubey (Founder) at NGM Biopharmaceuticals.
Where is NGM Biopharmaceuticals headquartered?
NGM Biopharmaceuticals is based in South San Francisco, California, United States.
How many employees does NGM Biopharmaceuticals have?
NGM Biopharmaceuticals is in the 101-250 employee band.
How does NGM Biopharmaceuticals' funding compare to other Biotechnology startups?
NGM Biopharmaceuticals' latest round of $122M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's NGM Biopharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NGM Biopharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.